Kamada Ltd. manufactures plasma-derived protein therapeutics. Products include KAMRAB/KEDRAB for rabies prophylaxis, CYTOGAM for CMV disease prevention, and VARIZIG for varicella post-exposure prophylaxis. Other products treat immune thrombocytopenic purpura, hemolytic disease of newborns, snake bites, and various conditions including cancer. The company also distributes imported drug products in Israel, including treatments for asthma, chronic obstructive pulmonary disease, and rheumatoid arthritis. Additionally, it distributes products for immunodeficiency-related conditions, hepatitis B, and hereditary factor X deficiency. Kamada was incorporated in 1990 and is headquartered in Rehovot, Israel.
| Indicator | Value |
|---|---|
| PER | 29.9 |
| EV/EBITDA | 16.2 |
| Price/Free Cash Flow' | 11.7 |
| ROIC | 13.3% |
| Net Debt/EBITDA | 0.7 |